Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, ...

DeepSeek has quickly gained attention in AI with its R1 model, which delivers high performance at a lower cost ... moving to Phase II, focusing on AI and cybernetics in drug development.

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

Rare diseases have become an attractive target for pharmaceutical companies both in Australia and internationally with ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Request To Download Free Sample of This Strategic Report@ Highlighted with 148 tables and 111 figures, this 241-page report ?Global Clinical Trials Market 2022-2031 by Product Category (Drugs, ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment ... Each company will be responsible for development costs in their respective regions and ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 99 tables and 79 figures, this 186-page report ?Europe Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices ...